Harrow, Inc. Share-based Payment Arrangement, Expense, after Tax
Harrow, Inc. (HROW) reported Share-based Payment Arrangement, Expense, after Tax of $240.06 thousand for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2014-11-12
- Harrow, Inc. share-based payment arrangement, expense, after tax for the quarter ending 2014-09-30 was $240.06K.
- Harrow, Inc. share-based payment arrangement, expense, after tax for the quarter ending 2014-06-30 was $318.82K.
- Harrow, Inc. share-based payment arrangement, expense, after tax for the quarter ending 2014-03-31 was $324.29K.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 9 month |
|---|---|---|---|
| 2014-09-30 | $240.06K 10-Q · filed 2014-11-12 | $558.88K derived: sum of 2 quarters · filed 2014-11-12 | $883.17K 10-Q · filed 2014-11-12 |
| 2014-06-30 | $318.82K 10-Q · filed 2014-08-13 | $643.12K 10-Q · filed 2014-08-13 | |
| 2014-03-31 | $324.29K 10-Q · filed 2014-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |